Document:

<PAGE>

EXHIBIT 10.25

                               FIFTH AMENDMENT TO
                       CONVERTIBLE SECURED PROMISSORY NOTE

      THIS FIFTH AMENDMENT TO CONVERTIBLE SECURED PROMISSORY NOTE (the "Fifth
Amendment") is made and entered into as of November 14, 2005, by and among
NORTHWEST BIOTHERAPEUTICS, INC., a Delaware corporation (the "Maker") and_______
(the "Holder"). This Fifth Amendment amends the Note (as defined below).

                                    RECITALS

A. Section 10 of that certain Convertible Secured Promissory Note, dated as of
November 12, 2003 and amended on April 26, 2004, April 12, 2005, June 16, 2005
and July 26, 2005, by and between the Maker and the Holder (as so amended the
"Note"), states that any provision of such note may be amended or waived in
writing by the Holder and the Maker; and

B. The Maker and the Holder wish to amend the Note as provided below.

                                    AGREEMENT

      NOW, THEREFORE, in consideration of these premises and for other good and
valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties hereto agree as follows:

1. Section 1 of the Note is hereby amended and restated in its entirety as
follows:

      "1. Maturity Date. The aggregate principal amount of this Note and accrued
interest thereon shall be due and payable on January 31, 2006 (such date, the
"Maturity Date")."

2. All other terms and conditions of the Note shall be unaffected hereby and
remain in full force and effect

3. This Fifth Amendment shall be shall be governed by and construed under the
laws of the State of Washington as applied to agreements among Washington
residents entered into and to be performed entirely within the State of
Washington.

4. This Fifth Amendment may be executed in one or more counterparts, each of
which will be deemed an original but all of which together shall constitute one
and the same agreement.

                            [SIGNATURE PAGE FOLLOWS]

                                        1
<PAGE>

      IN WITNESS WHEREOF, the parties hereto have executed this FIFTH AMENDMENT
TO CONVERTIBLE SECURED PROMISSORY NOTE as of the date first above written.

MAKER:

NORTHWEST BIOTHERAPEUTICS, INC.,
a Delaware corporation

By:________________________
Name:______________________
Title:_____________________

HOLDER:

___________________________
Name:

259046 v2/RE

                                        2<PAGE>

EXHIBIT 10.26

       AMENDMENT NO. 10 TO AMENDED AND RESTATED RECAPITALIZATION AGREEMENT

      THIS AMENDMENT NO. 10 TO AMENDED AND RESTATED RECAPITALIZATION AGREEMENT
(this "AMENDMENT") is made and entered into as of November 14, 2005 (the "TENTH
AMENDMENT DATE") by and between NORTHWEST BIOTHERAPEUTICS, INC., and its
affiliates, if any (collectively, the "COMPANY"), a Delaware corporation with
offices at 22322 20th Ave SE, Suite 150, Bothell, Washington, 98021, and TOUCAN
CAPITAL FUND II, L.P., and its designees (collectively, "INVESTOR"), a Delaware
limited partnership with offices at 7600 Wisconsin Avenue, Bethesda, MD 20814.
All capitalized terms used herein but not otherwise defined shall have the
meaning given such terms in the Agreement (as defined below).

                                    RECITALS

      WHEREAS, the Company and Investor have entered into that certain Amended
and Restated Recapitalization Agreement, dated as of July 30, 2004 (the
"AGREEMENT");

      WHEREAS, on October 22, 2004, the Company and Investor entered into
Amendment No. 1 to the Agreement;

      WHEREAS, on November 10, 2004, the Company and Investor entered into
Amendment No. 2 to the Agreement;

      WHEREAS, on December 27, 2004, the Company and Investor entered into
Amendment No. 3 to the Agreement;

      WHEREAS, on January 26, 2005, the Company and Investor entered into
Amendment No. 4 to the Agreement;

      WHEREAS, on April 12, 2005, the Company and Investor entered into
Amendment No. 5 to the Agreement;

      WHEREAS, on May 13, 2005, the Company and Investor entered into Amendment
No. 6 to the Agreement;

      WHEREAS, on June 16, 2005, the Company and Investor entered into Amendment
No. 7 to the Agreement;

      WHEREAS, on July 26, 2005, the Company and Investor entered into
Amendment No. 8 to the Agreement;

      WHEREAS, on September 7, 2005, the Company and Investor entered into
Amendment No. 9 to the Agreement;

                                       1
<PAGE>

      WHEREAS, the Company and Investor desire to further amend the Agreement to
make such changes to the Agreement as are set forth herein; and

      WHEREAS, Section 4.13(f) of the Agreement provides that the Agreement may
be amended or modified only by a written instrument signed by the Company and
Investor.

                                    AMENDMENT

      NOW, THEREFORE, for and in consideration of the mutual promises and
covenants set forth herein and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Company and
Investor hereby agree as follows:

1. Section 1.2 of the Agreement is hereby amended by inserting "and the Loan
Agreement, Security Agreement and 10% Convertible, Secured Promissory Note dated
November 14, 2005 attached hereto as Exhibit A-14, and the November 14 Bridge
Warrant (as defined herein) in the form attached hereto as Exhibit K-9"
immediately following the phrase "in the form attached hereto as Exhibit K-8" in
subsection (g) thereof.

2. Section 2.2(a) of the Agreement is hereby amended by replacing "A-13" with
"A-14."

3. Section 2.3(b) of the Agreement is hereby amended by adding the following
text immediately following the twenty-fourth sentence thereof:

      "On November 14, 2005 (the "TENTH AMENDMENT DATE"), Toucan Partners, LLC
      ("TOUCAN PARTNERS"), the designee of Toucan Capital Fund II, L.P., is
      providing an additional $400,000 of Bridge Funding (the "NOVEMBER 14
      BRIDGE FUNDING") to cover general operating expenses and certain other
      expenses of the Company agreed in advance by Investor during the period
      from November 14, 2005 through December 7, 2005. The November 14 Bridge
      Funding shall be evidenced by a Note in the form attached hereto as
      Exhibit A-14 and shall be provided on the terms and conditions set forth
      herein. The November 14 Bridge Funding shall be used only for the purposes
      and in the amounts agreed to in writing by Toucan Partners and the
      Company."

4. Section 2.3(b) of the Agreement is hereby further amended by replacing the
phrase "September 7 Bridge Funding" with "September 7 Bridge Funding or November
14 Bridge Funding") in the twenty-eighth sentence thereof (i.e., the
thirty-first sentence thereof after giving effect to the inclusion of the three
new sentences therein per Section 3 of this Amendment).

5. The Agreement is hereby amended by adding a new Section 2.19, immediately
following Section 2.18 thereof, as follows:

      "2.19 November 14 Bridge Warrant:

            (a) Issuance of November 14 Bridge Warrant. On the Tenth Amendment
      Date, Toucan Partners shall receive a warrant with coverage equal to one
      hundred percent (100%) of the principal amount due under the Note
      evidencing the November 14 Bridge Funding (the "NOVEMBER 14 BRIDGE
      WARRANT"). The Company shall, therefore, issue $400,000 in warrant
      coverage on the $400,000 of November 14 Bridge Funding provided on the
      Tenth Amendment Date. The number of shares subject to the November 14
      Bridge Warrant to be so issued shall be determined on the basis of $0.10
      per share (subject to adjustment for stock splits, stock dividends and the
      like). The total number of shares for which Toucan Partners shall
      initially be able to exercise the November 14 Bridge Warrant shall
      therefore be 4,000,000 shares as of the Tenth Amendment Date.

            (b) Exercise of November 14 Bridge Warrant. The November 14 Bridge
      Warrant shall be immediately exercisable upon issuance and continue to be
      exercisable for a period of seven (7) years after its issuance date. The
      exercise price of the November 14 Bridge Warrant shall be $0.04 (subject
      to adjustment for stock splits, stock dividends and the like, as provided
      more fully in the November 14 Bridge Warrant). In the event the
      Convertible Preferred Stock is approved and authorized, and the terms and
      conditions are the same as set forth herein and in the Convertible
      Preferred Stock Term Sheet, and

                                       2
<PAGE>
      Other Investors have purchased in cash (and not by conversion of debt,
      exercise of warrants or options, or conversion or exercise of other
      securities or instruments) a minimum of $15 million of such Convertible
      Preferred Stock, on the terms and conditions set forth herein and in the
      Convertible Preferred Stock Term Sheet, then the November 14 Bridge
      Warrant shall be exercisable solely for such Convertible Preferred Stock
      (subject to Section 5 thereof). However, if, for any reason, such
      Convertible Preferred Stock is not approved or authorized, and/or is
      approved or authorized on any terms different than any terms set forth
      herein and in the Convertible Preferred Stock Term Sheet, and/or if Other
      Investors have not purchased in cash (and not by conversion of debt,
      exercise of warrants or options, or conversion or exercise of other
      securities or instruments) a minimum of $15 million of such Convertible
      Preferred Stock, on the terms and conditions set forth herein and in the
      Convertible Preferred Stock Term Sheet, the November 14 Bridge Warrant
      shall be exercisable for any Equity Security and/or Debt Security (each as
      defined in Section 2.7 hereof) and/or any combination thereof, in each
      case that Investor shall designate in Investor's sole discretion (the
      securities so elected being the "INVESTOR DESIGNATED SECURITIES").

            (c) No Impairment. The Company shall not, by amendment of its
      Charter or through a reorganization, transfer of assets, consolidation,
      merger, dissolution, issue or sale of securities, or any other voluntary
      action, omission, or agreement, avoid or seek to avoid the observance or
      performance of any of the terms to be observed or performed by the Company
      under and/or in connection with the November 14 Bridge Warrant, but shall
      at all times in good faith use best efforts to assist in carrying out of
      all the provisions of and/or relating to such November 14 Bridge Warrant
      and in taking all such action as may be necessary or appropriate to
      protect Investor's rights, preferences and privileges under and/or in
      connection with the November 14 Bridge Warrant against impairment.
      Investor's rights, preferences and privileges granted under and/or in
      connection with the November 14 Bridge Warrant may not be amended,
      modified or waived without Investor's prior written consent, and the
      documentation providing for such rights, preferences and privileges will
      specifically provide as such.

            (d) Tax Treatment of November 14 Bridge Warrant and Note. The
      Company and Toucan Partners, as a result of arm's length bargaining, agree
      that the fair market value of the Note to be issued in connection with the
      November 14 Bridge Funding, if issued apart from the November 14 Bridge
      Warrant, is $396,000, and the fair market value of the November 14 Bridge
      Warrant, if issued apart from such Note, is $4,000. The Company and Toucan
      Partners further agree that all tax filings and records relating to or
      including this Agreement, the Note to be issued in connection with the
      November 14 Bridge Funding and/or the November 14 Bridge Warrant shall be
      prepared on the basis of, and consistently reflect, the agreed fair market
      values set forth in this Section 2.19(d), and the Company shall instruct
      its accountants and other tax-preparation professionals to prepare all tax
      filings and returns on the basis of the foregoing.

6. Section 3.4(b) of the Agreement is hereby amended by:

      (a)   replacing "$4.35 million" with "$3.95 million" in the first sentence
            thereof; and

      (b)   replacing "43,500,000" with "39,500,000" in the third sentence
            thereof.

7. Section 4.7.15 of the Agreement is hereby amended and restated in its
entirety as follows:

            "4.7.15 Liabilities. The Company has the following accrued
      liabilities: (i) tax liabilities to the State of Washington in the
      approximate amount of $329,243, (ii) amounts payable to Cognate
      Therapeutics and Investor, (iii) future sublease payments to MediQuest
      Corporation and a contingent lease liability to Benaroya Capital Company,
      LLC for the Company's premises should Mediquest Corporation default on its
      lease with Benaroya Capital Company, LLC and which is not yet due, and
      (iv) the Company's aggregate accrued, contingent and/or other liabilities
      of any nature, either mature or immature, as of the Tenth Amendment Date,
      not in excess of $407,126 (excluding amounts payable to Cognate and
      Investor), of which (x) $296,028 are currently due payables (including
      $212,021 for attorney fees), (y) $18,103 are the aggregate balances of
      capital leases payable in monthly installments in the amounts set forth in
      the budget included in the Schedule of Exceptions through the first
      calendar quarter of 2006, decreasing thereafter, the last of which is
      fully amortized in May 2007, and (z) $92,995 are accrued vacation and sick
      pay."

8. The AGREEMENT is hereby amended to add a new Section 4.14 as follows:

                                       3
<PAGE>

            "4.14 Designee. The parties hereto agree that Toucan Partners, LLC,
a Delaware limited liability company, as a designee of Toucan Capital Fund II,
L.P., is entitled to all rights, privileges and remedies afforded Investor by
this Agreement and all Related Recapitalization Documents, to the extent it
participates in any closing contemplated hereby."

9. The Agreement is hereby amended by adding new Exhibit A-14, immediately
following Exhibit A-13 thereto, in the form attached as Exhibit A-14 hereto.

10. Exhibit B to the Agreement, as amended on December 27, 2004, January 26,
2005, April 12, 2005, May 13, 2005, June 16, 2005, July 26, 2005 and September
7, 2005 is hereby further amended by Exhibit B-8 hereto (the "EIGHTH AMENDMENT
TO THE AMENDED AND RESTATED CONVERTIBLE PREFERRED STOCK TERM SHEET"). Exhibit B,
as so amended, shall be deemed to constitute the "CONVERTIBLE PREFERRED STOCK
TERM SHEET" for all purposes under the Agreement and all other Related
Recapitalization Documents.

11. The Agreement is hereby amended by adding new Exhibit K-9, immediately
following Exhibit K-8 thereto, in the form attached as Exhibit K-9 hereto.

12. The November 14 Bridge Warrant in the form attached hereto as Exhibit K-9
shall be deemed to be a "BRIDGE WARRANT" and a "WARRANT" for all purposes under
the Agreement and any Related Recapitalization Document. The Note evidencing the
November 14 Bridge Funding in the form attached hereto as Exhibit A-14 issued on
the Tenth Amendment Date shall be deemed to be a "NOTE" for all purposes under
the Agreement and any Related Recapitalization Document. Each of the November 14
Bridge Warrant and the Note evidencing the November 14 Bridge Funding shall be
deemed to be "RELATED RECAPITALIZATION DOCUMENTS" for all purposes under the
Agreement and all other Related Recapitalization Documents.

13. Except as amended and/or restated hereby, all other terms and conditions of
the Agreement shall be unaffected hereby and remain in full force and effect.

14. This Amendment (including the Exhibits hereto, which are an integral part of
the Amendment), together with the Agreement (including the Schedules and
Exhibits thereto, which are an integral part of the Agreement) and the Related
Recapitalization Documents, constitute the entire agreement among the parties
hereto and thereto with regard to the subjects hereof and thereof and supersede
all prior agreements and understandings relating to the subject matter hereof
and thereof.

15. This Amendment shall be governed by and construed under the laws of the
State of Delaware, without regard to its conflicts of law provisions.

16. This Amendment may be executed in one or more counterparts, each of which
will be deemed an original but all of which together shall constitute one and
the same agreement.

17. This Amendment shall take effect immediately upon execution by the Company
and Investor.

                  [REMAINDER OF PAGE LEFT INTENTIONALLY BLANK]

                                       4
<PAGE>

IN WITNESS WHEREOF, the parties hereto have executed this AMENDMENT NO. 10 TO
AMENDED AND RESTATED RECAPITALIZATION AGREEMENT as of the Tenth Amendment Date
above written.

            .

                                   NORTHWEST BIOTHERAPEUTICS, INC.

                                   By: /s/ Alton L. Boynton
                                       ----------------------------

                                   Name:  Alton L. Boynton
                                   Title:  President

                                   TOUCAN CAPITAL FUND II, LP

                                   By: /s/ Linda F. Powers
                                       ----------------------------
                                   Name:  Linda F. Powers
                                   Title:  Managing Director

                                   TOUCAN PARTNERS, LLC

                                   By: /s/ Linda F. Powers
                                       ----------------------------
                                   Name:  Linda F. Powers
                                   Title:  Managing Member

                                  EXHIBIT A-14

    FORM OF $400,000 LOAN AGREEMENT, SECURITY AGREEMENT AND 10% CONVERTIBLE,
                 SECURED PROMISSORY NOTE DATED NOVEMBER 14, 2005

                                       5
<PAGE>

                                   EXHIBIT B-8

     FORM OF EIGHTH AMENDMENT TO AMENDED AND RESTATED CONVERTIBLE PREFERRED
                                STOCK TERM SHEET

                                       6
<PAGE>

                                   EXHIBIT K-9
                        FORM OF NOVEMBER 14 BRIDGE WARRANT

                                       7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00093-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00093-of-00352.parquet"}]]